• Please log in or register to access this feature.

PAPER

You have free access to this content

Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas

  1. P. Rivera1,
  2. N. Åkerlund-Denneberg1,2,
  3. K. Bergvall1,3,
  4. M. Kessler1,4,
  5. A. Rowe1,5,
  6. M. Willmann1,6,
  7. G. Persson1,7,
  8. G. Kastengren Fröberg1,8,
  9. S. Westberg1,9,
  10. H. von Euler1

Article first published online: 27 NOV 2012

DOI: 10.1111/j.1748-5827.2012.01304.x

Issue

Journal of Small Animal Practice

Journal of Small Animal Practice

Volume 54, Issue 1, pages 20–27, January 2013

Additional Information

How to Cite

Rivera, P., Åkerlund-Denneberg, N., Bergvall, K., Kessler, M., Rowe, A., Willmann, M., Persson, G., Kastengren Fröberg, G., Westberg, S. and von Euler, H. (2013), Clinical efficacy and safety of a water-soluble micellar paclitaxel (Paccal Vet) in canine mastocytomas. Journal of Small Animal Practice, 54: 20–27. doi: 10.1111/j.1748-5827.2012.01304.x

Author Information

  1. 1

    Department of Clinical Sciences, Center of Clinical Comparative Oncology (C3O), Swedish University of Agricultural Sciences (SLU), Uppsala, Sweden

  2. 2

    Jönköping Small Animal Hospital, Jönköping, Sweden

  3. 3

    Djurakuten, Stockholm, Sweden

  4. 4

    Tierklinik, Hofheim, Germany

  5. 5

    Specialist Veterinary Hospital, Strömsholm, Sweden

  6. 6

    Department for Companion Animals and Horses, Clinic for Internal Medicine and Infectious Diseases, University of Veterinary Medicine, Vienna, Austria

  7. 7

    Region Animal Hospital, Helsingborg, Sweden

  8. 8

    Animal Hospital Albano, Danderyd, Sweden

  9. 9

    University Animal Hospital, SLU, Uppsala, Sweden

Publication History

  1. Issue published online: 26 DEC 2012
  2. Article first published online: 27 NOV 2012

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (793K)

References

  • VCOG-CTCAE (2004) Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Veterinary and Comparative Oncology 2, 195-213
  • Alektiar, K. M., Makker, V., Abu-Rustum, N. R., Soslow, R. A., Chi, D. S., Barakat, R. R. & Aghajanian, C. A. (2009) Concurrent carboplatin/paclitaxel and intravaginal radiation in surgical stage I-II serous endometrial cancer. Gynecologic Oncology 112, 142-145
  • Davies, D. R., Wyatt, K. M., Jardine, J. E., Robertson, I. D. & Irwin, P. J. (2004) Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors. Journal of the American Animal Hospital Association 40, 124-130
  • Di Lorenzo, G., Montesarchio, V., Autorino, R., Bellelli, T., Longo, N., Imbimbo, C., Morelli, E., Giannarini, G., Mirone, V. & De Placido, S. (2009) Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients. Cancer 115, 517-523
  • Dobson, J. M. & Scase, T. J. (2007) Advances in the diagnosis and management of cutaneous mast cell tumours in dogs. Journal of Small Animal Practice 48, 424-431
  • Dorn, C. R., Taylor, D. O., Schneider, R., Hibbard, H. H. & Klauber, M. R. (1968) Survey of animal neoplasms in Alameda and Contra Costa Counties. California. II. Cancer morbidity in dogs and cats from Alameda County. Journal of the National Cancer Institute 40, 307-318
  • Einzig, A. I. (1994) Review of phase II trials of Taxol (paclitaxel) in patients with advanced ovarian cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology/ESMO 5(Suppl 6), S29-32
  • Einzig, A. I., Hochster, H., Wiernik, P. H., Trump, D. L., Dutcher, J. P., Garowski, E., Sasloff, J. & Smith, T. J. (1991) A phase II study of taxol in patients with malignant melanoma. Investigation of New Drugs 9, 59-64
  • Fulcher, R. P., Ludwig, L. L., Bergman, P. J., Newman, S. J., Simpson, A. M. & Patnaik, A. K. (2006) Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs. Journal of the American Veterinary Medical Association 228, 210-215
  • Gatzemeier, U., Heckmayr, M., Neuhauss, R., Schluter, I., Pawel, J. V., Wagner, H. & Dreps, A. (1995) Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer 12(Suppl 2), S101-106
  • Gerritsen, R. J., Teske, E., Kraus, J. S. & Rutteman, G. R. (1998) Multi-agent chemotherapy for mast cell tumours in the dog. Veterinary Quarterly 20, 28-31
  • Grant, I. A., Rodriguez, C. O., Kent, M. S., Sfilgoi, G., Gordon, I., Davis, G., Lord, L. & London, C. A. (2008) A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors. Journal of Veterinary Internal Medicine 22, 388-393
  • Gueritte, F. (2001) General and recent aspects of the chemistry and structure-activity relationships of taxoids. Current Pharmaceutical Design 7, 1229-1249
  • Hahn, K. A., Ogilvie, G., Rusk, T., Devauchelle, P., Leblanc, A., Legendre, A., Powers, B., Leventhal, P. S., Kinet, J. P., Palmerini, F., Dubreuil, P., Moussy, A. & Hermine, O. (2008) Masitinib is safe and effective for the treatment of canine mast cell tumors. Journal of Veterinary Internal Medicine 22, 1301-1309
  • Hassan, S., Dhar, S., Sandstrom, M., Arsenau, D., Budnikova, M., Lokot, I., Lobanov, N., Karlsson, M. O., Larsson, R. & Lindhagen, E. (2005) Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo. Cancer Chemotherapy and Pharmacology 55, 47-54
  • Hume, C. T., Kiupel, M., Rigatti, L., Shofer, F. S., Skorupski, K. A. & Sorenmo, K. U. (2011) Outcomes of dogs with grade 3 mast cell tumors: 43 cases (1997-2007). Journal of the American Animal Hospital Association 47, 37-44
  • Jones, C. L., Grahn, R. A., Chien, M. B., Lyons, L. A. & London, C. A. (2004) Detection of c-kit mutations in canine mast cell tumors using fluorescent polyacrylamide gel electrophoresis. Journal of Veterinary Diagnostic Investigation 16, 95-100
  • Jordan, M. A. (2002) Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Current Medicinal Chemistry. Anti-cancer Agents 2, 1-17
  • London, C. A. & Seguin, B. (2003) Mast cell tumors in the dog. The Veterinary Clinics of North America. Small Animal Practice 33, 473-489, v
  • London, C. A., Malpas, P. B., Wood-Follis, S. L., Boucher, J. F., Rusk, A. W., Rosenberg, M. P., Henry, C. J., Mitchener, K. L., Klein, M. K., Hintermeister, J. G., Bergman, P. J., Couto, G. C., Mauldin, G. N. & Michels, G. M. (2009) Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research 15, 3856-3865
  • Marupudi, N. I., Han, J. E., Li, K. W., Renard, V. M., Tyler, B. M. & Brem, H. (2007) Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opinion on Drug Safety 6, 609-621
  • McCaw, D. L., Miller, M. A., Ogilvie, G. K., Withrow, S. J., Brewer, W. G. Jr., Klein, M. K., Bell, F. W. & Anderson, S. K. (1994) Response of canine mast cell tumors to treatment with oral prednisone. Journal of Veterinary Internal Medicine 8, 406-408
  • McCaw, D. L., Miller, M. A., Bergman, P. J., Withrow, S. J., Moore, A. S., Knapp, D. W., Fowler, D. & Johnson, J. C. (1997) Vincristine therapy for mast cell tumors in dogs. Journal of Veterinary Internal Medicine 11, 375-378
  • Murphy, S. (2003) Mast cell tumours. In: BSAVA Manual of Canine and Feline Oncology. 2nd edn. Eds J. Dobson and B. D. X. Lascelles. BSAVA, Glouchester. pp 161-167
  • Owen, L. N. (1980) TNM classification of tumours in domestic animals. In: TNM Classification of Tumours in Domestic Animals. 1st edn. Ed L. N. Owen. World Health Organization, Geneva, Switzerland
  • Pasquier, E., Carre, M., Pourroy, B., Camoin, L., Rebai, O., Briand, C. & Braguer, D. (2004) Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Molecular Cancer Therapy 3, 1301-1310
  • Patnaik, A. K., Ehler, W. J. & MacEwen, E. G. (1984) Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Veterinary Pathology 21, 469-474
  • Penel, N., Lansiaux, A. & Adenis, A. (2007) Angiosarcomas and taxanes. Current Treatment Options in Oncology 8, 428-434
  • Peters, J. A. (1969) Canine mastocytoma: excess risk as related to ancestry. Journal of the National Cancer Institute 42, 435-443
  • Poirier, V. J., Hershey, A. E., Burgess, K. E., Phillips, B., Turek, M. M., Forrest, L. J., Beaver, L. & Vail, D. M. (2004) Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors. Journal of Veterinary Internal Medicine 18, 219-222
  • Rassnick, K. M., Moore, A. S., Williams, L. E., London, C. A., Kintzer, P. P., Engler, S. J. & Cotter, S. M. (1999) Treatment of canine mast cell tumors with CCNU (lomustine). Journal of Veterinary Internal Medicine 13, 601-605
  • Rau, S. E., Barber, L. G. & Burgess, K. E. (2010) Efficacy of maropitant in the prevention of delayed vomiting associated with administration of doxorubicin to dogs. Journal of Veterinary Internal Medicine 24, 1452-1457
  • Romansik, E. M., Reilly, C. M., Kass, P. H., Moore, P. F. & London, C. A. (2007) Mitotic index is predictive for survival for canine cutaneous mast cell tumors. Veterinary Pathology 44, 335-341
  • Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Arbuck, S. G. & Donehower, R. C. (1993) Clinical toxicities encountered with paclitaxel (Taxol). Seminars in Oncology 20, 1-15
  • Swain, S. M., Honig, S. F., Tefft, M. C. & Walton, L. (1995) A phase II trial of paclitaxel (Taxol) as first line treatment in advanced breast cancer. Investigation of New Drugs 13, 217-222
  • Taylor, F., Gear, R., Hoather, T. & Dobson, J. (2009) Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases. Journal of Small Animal Practice 50, 284-289
  • Thamm, D. H., Turek, M. M. & Vail, D. M. (2006) Outcome and prognostic factors following adjuvant prednisone/vinblastine chemotherapy for high-risk canine mast cell tumour: 61 cases. Journal of Veterinary Medical Sciences 68, 581-587
  • Theilen, G. H. (1987) Performance status score. In: Veterinary Cancer Medicine. 2nd edn. Eds G. H. Theilen and B. R. Madewell. Lea and Febiger, Philadelphia, PA. USA. p 59
  • Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C. & Gwyther, S. G. (2000) New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 92, 205-216
  • Vail, D. M. (2009) Supporting the veterinary cancer patient on chemotherapy: neutropenia and gastrointestinal toxicity. Topics in Companion Animal Medicine 24, 122-129
  • Vail, D. M., von Euler, H., Rusk, A. W., Barber, L., Clifford, C., Elmslie, R., Fulton, L., Hirschberger, J., Klein, M., London, C., Martano, M., McNiel, E. A., Morris, J. S., Northrup, N., Phillips, B., Polton, G., Post, G., Rosenberg, M., Ruslander, D., Sahora, A., Siegel, S., Thamm, D., Westberg, S. & Winter, J. (2012) A randomized trial investigating the efficacy and safety of water soluble micellar paclitaxel (Paccal Vet) for treatment of nonresectable grade 2 or 3 mast cell tumors in dogs. Journal of Veterinary Internal Medicine 26, 598-607
  • Vaughan, A., Johnson, J. L. & Williams, L. E. (2007) Impact of chemotherapeutic dose intensity and hematologic toxicity on first remission duration in dogs with lymphoma treated with a chemoradiotherapy protocol. Journal of Veterinary Internal Medicine 21, 1332-1339
  • von Euler, H., Rivera, P., Nyman, H., Häggstrom, J. & Borgå, O. (2012) A dose-finding study with a novel water-soluble formulation of paclitaxel for the treatment of malignant high-grade solid tumours in dogs. Veterinary and Comparative Oncology [E-Pub ahead of print, Mar 9]
  • Zavodovskaya, R., Chien, M. B. & London, C. A. (2004) Use of kit internal tandem duplications to establish mast cell tumor clonality in 2 dogs. Journal of Veterinary Internal Medicine 18, 915-917
View Full Article with Supporting Information (HTML) Get PDF (793K)